RecruitingInterventional · Phase 2NCT05999240 ↗A Target Engagement Study of Pimavanserin for Behavioral Inflexibility With Open Label Trial for Rigid Rigid-compulsive Behavior in Adolescents and Adults With Autism
RecruitingInterventional · Phase 2NCT07091279 ↗Randomized Controlled Trial of Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With AutismKaren TangPIInterventionDrug: Propranolol · Drug: PlaceboDatesJan 2026 – Nov 2028 (est.)SponsorNew York State Pyschiatric InstituteAutism Spectrum DisorderChallenging BehaviourAggression+2 more
CompletedInterventional · Not applicableNCT04146428 ↗Evaluating BOSCC and ELSA as Outcome Measures in the Context of a JASPER Intervention TrialSo Hyun KimPIInterventionBehavioral: clinician-mediated JASPER · Behavioral: parent-mediated JASPERDatesApr 2021 – May 2025SponsorWeill Medical College of Cornell UniversityAutism Spectrum Disorder
CompletedInterventional · Phase 2NCT05067582 ↗A Randomized, Double-Blind, Chronic Dosing (12-weeks), Two-Period, Placebo-Controlled, Crossover, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Two Doses of L1-79 for the Treatment of the Core Deficits in Social-Communication Interaction in Adolescents and Young Adults With Autism Spectrum DisorderKaren TangPIInterventionDrug: L1-79DatesJan 2022 – Jun 2024SponsorYamo PharmaceuticalsAutism Spectrum DisorderAutism
CompletedInterventional · Phase 2NCT05081245 ↗A Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD).Karen TangPIInterventionDrug: ML-004 (IR)/(ER) tablet · Drug: ML-004 PlaceboDatesSep 2022 – Mar 2026SponsorMapLight Therapeutics, IncAutism Spectrum Disorder